Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.74 |
| ▸ | MAPT | P10636 | 6/20 | 0.74 |
| ▸ | TP53 | P04637 | 5/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 5/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | RECQL | P46063 | 2/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1058712 | 0.88 | HPGD (0.78) | HPGDCYP3A4MAPTTP53CYP2C19 | |
| SCHEMBL30143812 | 0.88 | HPGD (0.78) | HPGDCYP3A4MAPTTP53CYP2C19 | |
| SCHEMBL6241468 | 0.85 | MEN1 (0.74) | HPGDCYP3A4MAPTTP53CYP2C19 | |
| SCHEMBL722615 | 0.85 | HPGD (1.00) | HPGDCYP3A4MAPTTP53CYP2C19 | |
| SCHEMBL7583434 | 0.80 | HPGD (0.70) | HPGDCYP3A4MAPTTP53CYP2C19 | |
| SCHEMBL505415 | 0.78 | DHFR (0.68) | HPGDCYP3A4MAPTTP53CYP2C19 | |
| SCHEMBL27806529 | 0.78 | HPGD (0.67) | HPGDCYP3A4MAPTTP53CYP2C19 | |
| SCHEMBL4277649 | 0.78 | MAPT (1.00) | HPGDCYP3A4MAPTTP53CYP2C19 | |
| SCHEMBL12378837 | 0.78 | PTPRS (0.78) | HPGDCYP3A4MAPTTP53CYP2C19 | |
| SCHEMBL9148162 | 0.77 | MEN1 (0.79) | HPGDCYP3A4MAPTTP53CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150044193-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION | NEURALTUS PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | claimed |
| US-8669048-B2 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2014-03-11 | — | — | US | claimed |
| US-20120052053-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION | THE PARKINSON'S INSTITUTE | 2012-03-01 | — | — | US | claimed |
| EP-2361089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED -SYNUCLEIN FUNCTION | Parkinson's Institute (US) | 2011-08-31 | — | — | EP | claimed |
| US-20100167286-A1 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2010-07-01 | — | — | US | claimed |
| WO-2010056413-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION | PARKINSON'S INSTITUTE (US) | 2010-05-20 | — | — | WO | claimed |
| WO-2010008486-A2 | PLURIPOTENT CELL LINES AND METHODS OF USE THEREOF | PARKINSONS INSTITUTE (US) | 2010-01-21 | — | — | WO | claimed |
| US-10233422-B2 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170114324-A1 | PLURIPOTENT CELL LINES AND METHODS OF USE THEREOF | TYLER MEDICAL RESEARCH, LLC | 2017-04-27 | — | — | US | disclosed |
| US-9464273-B2 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150044193-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION | NEURALTUS PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20140356455-A1 | PLURIPOTENT CELL LINES AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-12-04 | — | — | US | disclosed |
| US-8669048-B2 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2014-03-11 | — | — | US | disclosed |
| US-20100167286-A1 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2010-07-01 | — | — | US | disclosed |
| WO-2010056413-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION | PARKINSON'S INSTITUTE (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010008486-A2 | PLURIPOTENT CELL LINES AND METHODS OF USE THEREOF | PARKINSONS INSTITUTE (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2009003147-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PARKINSON'S INSTITUTE (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007083904-A1 | C-KIT ACTIVATION INHIBITOR, SKIN WHITENING COMPOUND AND COMPOSITION FOR SKIN WHITENING CONTAINING THE SAME | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007083904-A1 | C-KIT ACTIVATION INHIBITOR, SKIN WHITENING COMPOUND AND COMPOSITION FOR SKIN WHITENING CONTAINING THE SAME | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | HPGD 1949/4885CYP3A4 17/4885MAPT 4566/4885 |
| US-20120052053-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION | SNCA, PARK7, NLN | HPGD 2116/4885CYP3A4 4355/4885MAPT 55/4885 |
| US-20150044193-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION | SNCA, PARK7, NLN | HPGD 2906/4885CYP3A4 4539/4885MAPT 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.